These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1650 related articles for article (PubMed ID: 20487414)

  • 1. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants.
    George B; Kerridge I; Gilroy N; Huang G; Hertzberg M; Gottlieb D; Bradstock K
    Bone Marrow Transplant; 2010 May; 45(5):849-55. PubMed ID: 19915635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
    Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
    Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.
    Piñana JL; Martino R; Barba P; Margall N; Roig MC; Valcárcel D; Sierra J; Rabella N
    Bone Marrow Transplant; 2010 Mar; 45(3):534-42. PubMed ID: 19668235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
    Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
    Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
    Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
    Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group.
    George B; Kerridge IH; Gilroy N; Huang G; Hertzberg MS; Bradstock KF; Gottlieb DJ
    Transpl Infect Dis; 2012 Apr; 14(2):141-8. PubMed ID: 22283838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
    Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
    Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus.
    Liu YC; Lu PL; Hsiao HH; Chang CS; Liu TC; Yang WC; Lin SF
    Ann Hematol; 2012 Apr; 91(4):587-95. PubMed ID: 21997849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
    Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
    Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation.
    Schönberger S; Meisel R; Adams O; Pufal Y; Laws HJ; Enczmann J; Dilloo D
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1428-35. PubMed ID: 20399877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
    Hazar V; Kansoy S; Küpesiz A; Aksoylar S; Kantar M; Yeşilipek A
    Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome.
    de Pagter PJ; Schuurman R; Visscher H; de Vos M; Bierings M; van Loon AM; Uiterwaal CS; van Baarle D; Sanders EA; Boelens J
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):831-9. PubMed ID: 18541204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation].
    Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Zhao XS; Yu L; Han W; Zhang XH; Wang Y; Chen Y; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):77-81. PubMed ID: 19563015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia.
    Schetelig J; Oswald O; Steuer N; Radonic A; Thulke S; Held TK; Oertel J; Nitsche A; Siegert W
    Bone Marrow Transplant; 2003 Oct; 32(7):695-701. PubMed ID: 13130317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
    Huang XJ; Xu LP; Ren HY; Zhang YC; Guo NL; Lu DP
    Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):766-9. PubMed ID: 12899755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation.
    Nachbaur D; Larcher C; Kircher B; Eibl G; Nussbaumer W; Gunsilius E; Haun M; Grünewald K; Gastl G
    Ann Hematol; 2003 Oct; 82(10):621-7. PubMed ID: 12920570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 83.